Trial Profile
Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms REGO-ACT
- Sponsors Bayer
- 12 Dec 2016 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016.